SCHEMBL610204

SCHEMBL610204

O=C([C@H]1CCCN(S(=O)(=O)c2c(Cl)cccc2Cl)C1)N(CC1CC1)C1CCC(O)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.50
LMNA P02545 4/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
ALDH1A1 P00352 3/20 0.50
HTT P42858 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
ALOX15 P16050 2/20 0.50
ATM Q13315 1/20 0.43
CNR1 P21554 1/20 0.42
HSD11B1 P28845 1/20 0.42
AKR1C3 P42330 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
AKR1C1 Q04828 1/20 0.40
POLB P06746 3/20 0.39
USP2 O75604 1/20 0.39
CCR1 P32246 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL610203 1.00 TSHR (0.50) TSHRLMNASMN1; SMN2ALDH1A1HTT
SCHEMBL4960486 0.89 HSD11B1 (0.57) TSHRLMNASMN1; SMN2ALDH1A1HTT
SCHEMBL609816 0.89 HSD11B1 (0.57) TSHRLMNASMN1; SMN2ALDH1A1HTT
SCHEMBL609817 0.89 HSD11B1 (0.57) TSHRLMNASMN1; SMN2ALDH1A1HTT
SCHEMBL612937 0.76 HSD11B1 (0.62) TSHRLMNASMN1; SMN2ALDH1A1ATM
SCHEMBL4963969 0.76 HSD11B1 (0.62) TSHRLMNASMN1; SMN2ALDH1A1ATM
SCHEMBL612938 0.76 HSD11B1 (0.62) TSHRLMNASMN1; SMN2ALDH1A1ATM
SCHEMBL28659036 0.70 ATM (0.64) LMNASMN1; SMN2ATMCNR1HSD11B1
SCHEMBL4962188 0.69 HSD11B1 (0.59) TSHRLMNASMN1; SMN2ALDH1A1ATM
SCHEMBL610159 0.69 HSD11B1 (0.59) TSHRLMNASMN1; SMN2ALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040964-A1 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-02-16 US claimed
US-20060004049-A1 N-substituted piperidines and their use as pharrmaceuticals INCYTE CORPORATION 2006-01-05 US claimed
US-8288417-B2 N-substituted piperidines and their use as pharmaceuticals INCYTE CORPORATION (US) 2012-10-16 US disclosed
US-20120040964-A1 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-02-16 US disclosed
US-8071624-B2 N-substituted piperidines and their use as pharmaceuticals INCYTE CORPORATION (US) 2011-12-06 US disclosed
EP-1758580-A4 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-16 EP disclosed
EP-1758580-A2 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-03-07 EP disclosed
WO-2006012226-A2 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20060004049-A1 N-substituted piperidines and their use as pharrmaceuticals INCYTE CORPORATION 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040964-A1 N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS HSD11B1, CYP11B1, HSD3B1 TSHR 1143/4885LMNA 2501/4885SMN1; SMN2 3943/4885
US-20060004049-A1 N-substituted piperidines and their use as pharrmaceuticals HSD11B1, HSD3B1, HSD11B2 TSHR 1444/4885LMNA 2826/4885SMN1; SMN2 4253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.